Abstract 2117P
Background
The provision of nutrients in adequate quantity and quality is essential for the treatment of low muscle mass, which is highly found in patients with lung cancer (LC). Identifying an early deficit in food consumption is recommended as a strategy to preserve muscle and weight compartments that directly impact treatment tolerance, functionality and quality of life. This study aimed to investigate whether caloric and protein intake at diagnosis are predictive of outcomes in patients with LC.
Methods
This is a prospective, observational study. Data were collected at the first nutritional consultation between January and December 2019 and consisted of nutritional risk screening for cancer patients, height, body weight, weight loss, calf circumference, handgrip strength measured using a dynamometer and 24-hour recall to estimate average food and macronutrient intake. Survival curves were generated by Kaplan-Meier analysis to assess the association between caloric and protein intake and 3-year mortality.
Results
A total of 50 patients with LC were included, 62% were female, 94% elderly, 88% with non-small cell lung cancer, 88% were diagnosed with disease stages III and IV, and 64% were smokers. Weight-adjusted mean daily intake of energy was 18.6 kcal/kg/day and protein 0.94g/kg/day, and 86% and 60% had lower energy and protein intakes, respectively, than the recommended for patients with cancer. Individuals with consumption greater than 1g/kg/day had significantly longer overall survival with 35,2 versus 21,9 months than those with consumption lower than the recommendation for patients with cancer (p=0.03). There was no statistical difference according to the caloric intake (>25kcal/kg/day versus <25kcal/kg/day) (p=0.20).
Conclusions
Caloric and protein intake at diagnosis is low in patients with LC, and a lower protein intake was a predictor of negative results. Nutritional interventions are low-cost and can be easily implemented as a strategy to modify these results and improve care for these individuals.
Clinical trial identification
Research Ethics Committee approval CAAE: 19918319.1.0000.5533.
Editorial acknowledgement
Legal entity responsible for the study
Grupo Oncoclínicas / Federal University of Rio de Janeiro.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2065P - Communication on the first medical oncology appointment: What do cancer patients want?
Presenter: Rodrigo Vicente
Session: Poster session 06
2066P - Evaluation of the quality and reliability of ChatGPT and Perplexity's responses about rectal cancer
Presenter: Ozan Yazici
Session: Poster session 06
2067P - Influence of psychiatric disorders on survival in patients with lung cancer: Real-world data
Presenter: Tomi Kovacevic
Session: Poster session 06
2068P - Perspectives and concerns on sexuality among adolescents and young adults treated for testicular germ cell tumour: The PRICELESS-study - A qualitative study
Presenter: Danielle Zweers
Session: Poster session 06
2069P - QoL changes of caregivers during first-line palliative chemotherapy for patients with incurable cancer
Presenter: Nobumichi Takeuchi
Session: Poster session 06
2070P - Assessment of healthy lifestyle habits in breast cancer patients
Presenter: Juan Cristobal Sanchez
Session: Poster session 06
2071P - Identification of top issues and concerns of cancer patients in Korea on social media
Presenter: Joo Han Lim
Session: Poster session 06
2072P - Topical application of mixed agents to reduce oral mucositis during radiotherapy in post operated head and neck cancer
Presenter: Chandra Prakash
Session: Poster session 06
2073P - Medical cannabis: A potential effective treatment for chemotherapy-induced peripheral neuropathy (CIPN)
Presenter: Ravit Geva
Session: Poster session 06
2074P - Oral cannabidiol for prevention of chemotherapy-induced peripheral neuropathy
Presenter: Sebastian Nielsen
Session: Poster session 06